NcXHF

SEQUENCING MYELOMA TREATMENTS
45. Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in
multiple myeloma relapsing after therapy with IMiDs and bortezomib: a
multicenter international myeloma working group study. Leukemia.
2012;26:149-157.
46. Richardson PG, Siegel DS, Vij R, et al. Pomalidomide alone or in combination
with low-dose dexamethasone in relapsed and refractory multiple
myeloma: a randomized phase 2 study. Blood. 2014;123:1826-1832.
47. San Miguel J, Weisel K, Moreau P, et al. Pomalidomide plus lowdose
dexamethasone versus high-dose dexamethasone alone for patients
with relapsed and refractory multiple myeloma (MM-003): a randomised,
open-label, phase 3 trial. Lancet Oncol. 2013;14:1055-1066.
48. Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent
carfılzomib (PX-171-003-A1) in patients with relapsed and refractory
multiple myeloma. Blood. 2012;120:2817-2825.
49. Vij R, Wang M, Kaufman JL, et al. An open-label, single-arm, phase 2
(PX-171-004) study of single-agent carfılzomib in bortezomib-naive patients
with relapsed and/or refractory multiple myeloma. Blood. 2012;
119:5661-5670.
50. Vij R, Siegel DS, Jagannath S, et al. An open-label, single-arm, phase 2
study of single-agent carfılzomib in patients with relapsed and/or refractory
multiple myeloma who have been previously treated with bortezomib.
Br J Haematol. 2012;158:739-748.
asco.org/edbook | 2015 ASCO EDUCATIONAL BOOK
e511